Stock Market Reviews

FBRX (Forte Biosciences, Inc.) News

Get the latest news, insights, and market updates on FBRX (Forte Biosciences, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
  There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Forte Biosciences...
  Feb 18, 2026 - $FBRX
• Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
  DALLAS, February 09, 2026--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will be presenting at two upcoming investor meetings.
  Feb 9, 2026 - $FBRX
• Chief Financial Officer of Forte Biosciences Picks Up 30% More Stock
  Investors who take an interest in Forte Biosciences, Inc. ( NASDAQ:FBRX ) should definitely note that the Chief...
  Jan 4, 2026 - $FBRX
• Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
  DALLAS, December 22, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
  Dec 22, 2025 - $FBRX
• Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year
  Key Insights Significantly high institutional ownership implies Forte Biosciences' stock price is sensitive to their...
  Dec 12, 2025 - $FBRX
• Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
  DALLAS, November 24, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
  Nov 24, 2025 - $FBRX
• Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
  DALLAS, November 14, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its third quarter 2025 financial results and provided a business update.
  Nov 14, 2025 - $FBRX
• Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
  DALLAS, October 03, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
  Oct 3, 2025 - $FBRX
• Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium
  DALLAS, September 15, 2025--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced additional details from the oral presentation "FB102 prevents histological damage and mitigates gluten challenge-induced symptoms in a celiac disease phase 1b study - Jason Tye-Din, Walter and Eliza Hall Institute; Royal Melbourne Hospital" at the Tampere Celiac Disease Symposium 2025 (Tampere, Finland
  Sep 15, 2025 - $FBRX
• We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Sep 11, 2025 - $FBRX